Biogen: Crohn Disease trials

The registry lists 11 Crohn Disease studies with Biogen as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 2Phase 3 3Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Real-world Study of Imraldi® UseCompletedNCT04089514
• One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyCompletedNCT03662919
• Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α TherapyWithdrawnNCT00801125Phase 4
• CD INFORM: Investigating Natalizumab Through Further Observational Research and MonitoringTerminatedNCT00707512
• Pregnancy Exposure Registry for Tysabri®CompletedNCT00472992
• Open Label Natalizumab Safety Extension Study for Subjects With Crohn's DiseaseCompletedNCT00280956Phase 4
• A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's DiseaseCompletedNCT00078611Phase 3
• Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's DiseaseCompletedNCT00055536Phase 2
• Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's DiseaseCompletedNCT00055367Phase 2
• Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCompletedNCT00032799Phase 3
• Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCompletedNCT00032786Phase 3